The murine Pten prostate cancer model described in this study recapitulates the disease progression seen in humans: initiation of prostate cancer with prostatic intraepithelial neoplasia (PIN), followed by progression to invasive adenocarcinoma, and subsequent metastasis with defined kinetics. Furthermore, while Pten null prostate cancers regress after androgen ablation, they are capable of proliferating in the absence of androgen. Global assessment of molecular changes caused by homozygous Pten deletion identified key genes known to be relevant to human prostate cancer, including those "signature" genes associated with human cancer metastasis. This murine prostate cancer model provides a unique tool for both exploring the molecular mechanism underlying prostate cancer and for development of new targeted therapies.
Introduction
. PTEN alteration is strongly implicated in prostate cancer development. PTEN deletions and/or mutations are Prostate cancer is the most common malignancy in men and found in 30% of primary prostate cancers (Dahia, 2000; Sellers the second leading cause of male cancer-related deaths in the and Sawyers, 2002) and 63% of metastatic prostate tissue samWestern world. Its development proceeds through a series of ples (Suzuki et al., 1998b) , placing PTEN mutation among the defined states, including prostatic intraepithelial neoplasia (PIN), most common genetic alterations reported in human prostate prostate cancer in situ, invasive and metastatic cancer. The cancers. PTEN-controlled signaling pathways are frequently altered standard therapies include androgen ablation that initially causes tumor regression. However, tumor cells will eventually in human prostate cancers, making them promising targets for therapeutic strategies (DeMarzo et al., 2003 ; Sellers and Sawrelapse and develop into hormone refractory prostate cancer (HRPC) (Denis and Murphy, 1993; Landis et al., 1999 Landis et al., ). yers, 2002 Vivanco and Sawyers, 2002) . The major function of the tumor suppressor PTEN relies on its phosphatase activity The PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor gene is one of the most and subsequent antagonism of the PI3K/AKT pathway (Cantley and Neel, 1999; Di Cristofano and Pandolfi, 2000 ; Maehama et frequently mutated/deleted genes in various human cancers (Bose et al., 2002; Deocampo et al., 2003; Sun et al., 2002; . Loss of PTEN function, either in murine embryonic stem cells or in human cancer cell lines, results in accumulation Wang et al., 2003; Zhou et al., 2002) . Germline mutations in the PTEN gene have been associated with Cowden syndrome and of PIP3 and activation of its downstream effectors, such as AKT/PKB (Stambolic et al., 1998; Sun et al., 1999 ; Wu et al., related diseases in which patients develop hyperplastic lesions (harmatomas) in multiple organs with increased risks of malig -1998) . As a serine/threonine protein kinase, AKT functions by phosphorylating key intermediate signaling molecules, such as nant transformation (Dahia, 2000; Liaw et al., 1997; glycogen synthase kinase-3 (GSK3), BAD, Caspase 9, and IB, Results leading to increased cell metabolism, cell growth, and cell surCre-mediated Pten homozygous deletion vival (Di Cristofano and Pandolfi, 2000; Hanahan and Weinberg, and upregulated AKT activity 2000; Vivanco and Sawyers, 2002) . Recent studies also suggest To achieve Pten prostate-specific deletion, we crossed Pten loxp/loxp that PTEN may function through AKT-independent mechanisms mice (Lesche et al., 2002) to the ARR2Probasin-Cre transgenic (Freeman et al., 2003; Gao et al., 2000; Weng et al., 2001) .
line, PB-Cre4, in which the Cre recombinase is under the control Inactivation of Pten in mouse models has confirmed PTEN of a modified rat prostate-specific probasin (PB) promoter (Wu as a bona fide tumor suppressor. Pten ϩ/Ϫ mice showed a broad et al., 2001) . By crossing PB-Cre4 to a conditional reporter spectrum of spontaneous tumor development, with a bias tomouse R26R, the original report indicated that Cre expression ward organs such as large and small intestines, lymphoid, mamis specific for prostatic epithelial cells. However, its expression mary, thyroid, endometrial, and adrenal glands (Di Cristofano levels vary from lobe to lobe: highest in the lateral lobe (LP), et al., Podsypanina et al., 1999; Stambolic et al., 2000;  followed by the ventral (VP), dorsal (DP), and least in anterior Suzuki et al., 1998a) . Since homozygous deletion of Pten causes lobes (AP) . Since Cre-mediated recombination early embryonic lethality, previous studies for prostate cancers event is a unidirectional process, cells with Cre-mediated gene caused by Pten deletion were invariably using Pten heterozydeletion are likely to increase and accumulate over time. Indeed, gous mice. Different rates of prostatic hyperplasia and cancer a recent follow up study indicated that Cre-mediated recombihave also been reported in the above studies. Our recent study nation events increased to near 100% in LP/VP/DP at the age demonstrated that Pten ϩ/Ϫ male mice on a Balb/c/129 genetic of 8 months (Powell et al., 2003 Figure 1A ), conpressor genes, as possible "second hits," have been generated. sistent with the previous report . Double immuPten ϩ/Ϫ ;p27 Ϫ/Ϫ mice develop prostate carcinoma within 3 nofluorescent analysis demonstrated that PTEN is highly exmonths postnatally with complete penetrance (Di Cristofano et pressed in cytoplasm and less so in the nucleus of prostatic al., 2001). Pten ϩ/Ϫ ;Nkx3.1 Ϫ/Ϫ compound mutant mice display an epithelial cells lining the prostatic acini as well as the stromal increased incidence of high-grade PIN but not prostate cancer cells surrounding the acini ( Figure 1B , left panel; PTEN in red). (Kim et al., 2002) . Similarly, Ink4a/Arf deficiency reduced tumorDeletion efficiencies of the Pten floxed alleles in different lobes free survival and shortened the latency of PIN associated with were similar to the Cre expression pattern reported previously: Pten heterozygosity (You et al., 2002) . However, no metastatic PTEN immunostaining is significantly reduced in the lateral and prostate cancers were reported in these models (Di Cristofano ventral lobes but only lost or diminished in a subset of the cells et Kim et al., 2002; You et al., 2002) . Pten heterozygous in the dorsal and anterior lobes of 4-week-old Pten loxp/loxp ;PBmice were also crossed with the well-characterized TRAMP Cre4 ϩ mice (Supplemental Figure S1 at http://www.cancercell. model (Greenberg et al., 1995) . Pten LOH significantly shortened org/cgi/content/full/4/3/209/DC1, LP from WT and mutant mice the average life span of TRAMP mice from 245 days to 159 days are shown here). By 9 weeks, a majority of the cells in the (Kwabi-Addo et al., 2001 ). More recently, the MPAKT model was epithelial compartment of DLP and VP show loss of PTEN immucreated that expressed constitutively activated AKT in mouse nostaining, and approximately 40%-60% cells in the AP are prostate epithelial cells (Majumder et al., 2003) . The MPAKT PTEN null ( Figure 1B , right panels; PTEN in red). Furthermore, mice develop PIN lesions in the ventral prostate with prominent PTEN immunostaining in the stromal compartment remains posbladder obstruction. No progression to metastatic prostate canitive, further confirming Pten epithelial-specific deletion. cer was reported (Majumder et al., 2003) .
As a result of PTEN loss, the AKT serine/threonine kinase, To assess whether Pten homozygous deletion is critical for one of the primary targets of the PTEN-controlled signaling prostate cancer progression, we generated Pten loxp/loxp ;PB-Cre4 pathway, is activated. Thus, AKT phosphorylation and plasma mice to achieve prostate-specific Pten deletion. Our studies membrane localization can serve as reliable indicators for PTEN demonstrated that Pten LOH leads to a significant shortened loss. AKT phosphorylation is rarely detectable in the WT prostate latency of PIN formation and results in prostate cancer progres-( Figure 1B , left panels; P-AKT in green; also see Supplemental sion to a metastatic stage, mimicking the disease progression Figure S1B on Cancer Cell website) but is highly expressed in seen in humans. The Pten conditional prostate deletion mice Pten null cells, especially at the plasma membrane of the DLP also provide a unique opportunity to address the mechanism of and VP ( Figure 1B , right panels; also see Supplemental Figure  resistance to androgen ablation therapy in a genetically defined S1F). Pten null, AKT-activated cells were also larger than their model where the initiating oncogenic event is not androgen dependent. Our characterization of the Pten model by expres-WT or heterozygous control cells (Supplemental Figure S1 , inserts), consistent with the role of PTEN in controlling cell size sion profiling has further indicated that the Pten model has many additional similarities to human prostate cancers.
( cific deletion from 4 to 29 weeks. To avoid potential variations contributed by genetic background, only mice from the F2 generation were used for studies described below. Deletion of both alleles of Pten led to progressively enlarged prostate glands. Histological analysis indicated that from 4 weeks on, the prostates of the mutant mice developed multifocal hyperplasia. These were initially observed in the dorsolateral and ventral lobes and subsequently involved the anterior lobes as well, consistent with the efficiency of Cre-mediated Pten deletion. Figure 2A shows a comparison of dorsolateral lobes from WT and their Pten null littermates from 4 to 12 weeks. Epithelial hyperplasia, characterized by increased number of cells (without cellular atypia), is seen by 4 weeks of age ( Figure  2A , a compared to b). By 6 weeks of age, these mice develop murine PIN (mPIN). mPIN is the proliferation of atypical epithelial cells within pre-existing prostatic ductules and acini ( Figure 2Ad and supplemental Figure S2A on Cancer Cell website). This proliferation results in stratification of the epithelial layer, giving rise to distinctive architectural features, to include cribiform, tufting, or micropapillary growth patterns (Figure 2Ad ). Cytological atypia is characterized by nuclear enlargement, nuclear contour irregularity, hyperchromatism, and prominent nucleoli accompanied by the inversion of the nuclear to cytoplasmic ratio ( Figure 2Ac compared to 2Ad; arrows point to atypical cells). One hundred percent of the homozygous mice developed mPIN at 6 weeks (Table 1) . Thus, homozygous Pten deletion significantly shortened the latency for mPIN formation from 8-10 months in heterozygous to 1.5 months in homozygous conditional knockouts. Significantly, Pten null mPIN lesions progress to invasive and metastatic cancers (see below). These results demonstrate that (1) homozygous PTEN loss alone is sufficient for prostate cancer initiation; and (2) Pten LOH is a rate-limiting step for prostate cancer initiation and progression. found in association with the invasive cancer. These prostate cancer cells show increased proliferation compared to the WT controls, as indicated by their Ki67-positive staining ( Figure 2B , left panels).
Homozygous
Prostate epithelium includes basal cells, luminal cells, and Pten homozygous deletion shortens latency neuroendocrine cells. Transgenic mice overexpressing the onfor mPIN formation cogenic SV40 T antigen (Garabedian et al., 1998 ; Greenberg et To determine whether deletion of both alleles at the Pten locus, al., 1995; Kasper et al., 1998; Masumori et al., 2001 ) develop or loss of heterozygosity (LOH), is required for prostate cancer both adenocarcinoma and neuroendocrine carcinoma. cells in normal and neoplastic prostate are devoid of androgen noma, i.e., epithelial origin, differing from T antigen transgenic mice in which tumors are of neuroendocrine origin. receptor (AR) and are positive for chromogranin A and synaptophysin (SNP) (for review, see Sciarra et al., 2003) . As shown in Figure 2B , Pten null cancer cells were AR positive ( Figure 2B , Homozygous Pten deletion leads to metastatic prostate cancers left panels), a hallmark of secretory epithelium, but were negative for the neuroendocrine cell marker synaptophysin ( Figure 2B , Similar to the progression of human prostate cancers, Pten null prostate cancers also progress from mPIN to invasive adenocarmiddle panels). Thus, Pten deletion results in an adenocarcicinoma, then to metastatic carcinoma with precisely defined kinetics. We have observed lymphovascular invasion in the Pten conditional knockout mice from 12 weeks of age (present in In response to androgen withdrawal, the AR-positive prostatic epithelium undergoes increased apoptosis, as indicated by dramatically increased TUNEL-positive cells, which results in a reduction of prostate volume following castration (Supplemental Figures S4 and S5 on Cancer Cell website). In the WT control prostate, cell death can be easily detected 3 days after castration and peaks around 6 days ( Figure 4A , TUNELϩ cells in brown; blue bars on the right panel show quantification). Even though PTEN is known for its role in negatively regulating apoptosis (Di Cristofano et al., 1998) , quantitative analysis indicates that there is almost 10 times increase of apoptotic cells in the Pten null prostate 3 days post-castration compared with intact animal ( Figure 4A , red bars; p Ͻ 0.005), suggesting that the survival of Pten null prostate cancer cells is androgen dependent. The percentage of apoptotic cell drops when the measurement is taken at 6 days post-castration ( Figure 4A , p Ͻ 0.005), indicating that Pten null prostate cancer cells may adapt to the new condition and exhibit enhanced survival, or the androgensensitive population has been gradually depleted.
To test whether mice with Pten null prostate cancer would benefit from androgen ablation therapy, we castrated Pten conditional knockouts at 2.5-4 months when invasive adenocarcinoma has already formed. For intact mice, 3/14 Pten prostate conditional knockouts died by the age of 12-29 weeks (Table  1) . In contrast, no lethality is observed in 8/8 castrated Pten null mice aged from 7-10 months, indicating that Pten null prostate cancers do benefit from androgen ablation therapy. However, when these mice were sacrificed 2.5 months after castration, we found that a substantial number of Pten null prostate cancer cells remained ( Figure 5 ). Histological analysis demonstrates that Pten null prostate glands remain 5-to 10-fold larger when compared to age-matched WT controls ( Figure 5 , left panels; comparing LP of WT and mutant). Residual invasive adenocarcinoma is clearly evident ( Figure 5 , lower middle panel; red arrows point to cords of cancerous cells coursing through desmoplastic stroma). This enlargement, at least in part, is due to the higher proliferation index in the Pten null prostate. Figure 4B shows Ki67 staining and quantification ( Figure 4B) . Surprisingly, the proliferation indexes of Pten null prostate are 17-fold higher than age-and genetic background-matched WT controls at 3 days, as well as 6 days and 10 weeks, after castration and are androgen, as indicated by the higher percentage of TUNELpositive cells found in Pten null prostate 10 weeks after castration ( Figure 4A ). Even though the remaining adenocarcinoma in right panel). Thus, the conditional Pten null mouse represents Pten conditional knockouts did not lead to premature death the first animal model in which deletion of an endogenous gene during the short observation period, the knockouts may have leads to metastatic prostate cancer.
the potential, as indicated by their ability to proliferate in the absence of androgen, to develop into HRPC, similar to that of Pten null prostate tumors do respond to castration humans, after prolonged castration. Androgens are critical both for development and function of the normal prostate gland and for the survival and proliferation of Gene expression analysis revealed similarities between prostate cancer cells. To assess the response of Pten null prosmolecular mechanisms underlying Pten null murine tate cancers to hormone ablation therapy, we castrated Pten cancers and human prostate cancers conditional knockout mice at 16 weeks, when invasive adenoTo provide insights into the molecular events associated with prostate tumorigenesis, we compared gene-expression profiles carcinoma has already formed, and analyzed the immediate of Pten null prostates with age-matched WT controls using in Figures 6B and 6C and summarized in Figure 7 , some changes, such as Nkx3.1 and clusterin (also see Supplemental microarray analysis. Our initial studies were focused on animals 26-29 weeks of age since 100% of mutant animals at this stage Figure S1 ), are directly associated with homozygous Pten deletion and may be regulated by a PTEN-controlled signaling pathhave already developed invasive adenocarcinoma. Half of the prostate was fast frozen for RNA preparation and the other way; other changes are observed during tumor progression, such as PSCA ( Figure 6B ), or related to metastasis (osteopontin, half was fixed for pathological evaluation. Histological analysis indicated that more than 80% of the Pten null prostate tissue Z. Song and P.R.-B., personal communication). These later groups may represent the additional genetic alterations associat this stage was composed by microinvasive cancer cells and mPIN and less than 20 percent by stoma and inflammatory cells ated with prostate cancer development (Figure 7 ). Clusterin (Steinberg et al., 1997) and osterpontin (Hotte et al., 2002) are (data not shown). Statistical analysis of 10290 mouse genes/ ESTs generated a list of 1041 significantly altered genes/ESTs secreted molecules and could be used as potential biomarkers for cancer staging and molecular diagnostics. (Table S1 in Supplemental Data). Among them, 579 are upregulated in Pten null cancer and 462 are downregulated, and the Recently, molecular signatures of metastatic potential have been found within the bulk cell mass of primary tumors, sugtop 50 up-and downregulated genes are shown in Figure 6A .
Gene expression changes in the Pten null prostate cancers gesting that metastasis may be an intrinsic property inherited in the primary cancers (Ramaswamy et al., 2003 ; van 't Veer included orthologs of genes whose expression also changes in human prostate cancers, such as upregulated cyclin A, clusterin, et al., 2002) . Interestingly, among 17 such "signature genes" identified in various human cancers, three genes, namely PSCA, S100P, ERG-1, and osteopontin, as well as down regulated Nkx3.1 and myosin heavy chain 11 (Aaltomaa et al., 1999;  Col1␣1, Col1␣2, and Myh11, are also up-or downregulated in our Pten prostate models ( Figure 6A , genes are marked with *), Bowen et al., 2000; Dhanasekaran et al., 2001; Gu et al., 2000; He et al., 1997; Hotte et al., 2002; Mousses et al., 2002; Rama- consistent with the metastasis potential of Pten prostate cancer cells described in this study. Taken together, our initial characswamy et al., Reiter et al., 1998; Steinberg et al., 1997) . The corresponding protein expression levels of selected genes, terization of changes in gene expression profiling suggests that the Pten prostate model will be useful to provide insights into which are underlined in Figure 6A , were further confirmed by immunohistological staining or Western blot analysis. As shown the molecular events associated with prostate cancer progres- sion and metastasis and to elucidate biomarkers and drug tarTp53, and Cdkn1B, has yielded little information regarding their gets for clinical classification and therapeutic intervention. involvement in prostate cancer development. Mice lacking Rb1 are embryonic lethal, and Tp53, Cdkn1B (p27KIP1), or Nkx3.1 Discussion deletion either has no effect on prostate cancer development (Tp53 and Cdkn1B) (Powell et al., 2003) or results in only a Animal models for human prostate cancer hyperplasia/dysplasia phenotype in aged animals (Nkx3.1) (AbAnimal models that mimic genetic alterations and clinical dulkadir et al., 2002; Bhatia-Gaur et al., 1999; Tanaka et al., courses of human prostate cancer are at high demand for the 2000). study of the molecular mechanisms underlying prostate tumorAs summarized in Figure 7 , the Pten prostate cancer model genesis and for innovation and validation of new anti-cancer mimics the course of human prostate cancer formation: it progstrategies. Currently available models for prostate cancer reresses from hyperplasia to mPIN, then to invasive adenocarcisearch include Huggins' spontaneous canine model, the Dunnoma, followed by matastasis. Histologically, the Pten null tumor ning and Noble rat models, the prostate organ reconstitute is derived from secretive epithelium, similar to the origin of the model, and several transgenic mouse models (Powell et al., majority of human prostate tumors. Notably, the invasive Pten 2003). Mouse models, created via either transgenic or knockout null prostate cancer cells do respond to androgen ablation, approaches, are more frequently utilized than the canine or rat as indicated by increased apoptosis, similar to most human models because of their clearly defined genetics and molecular prostate cancers. Even though the survival of Pten null prostate targets. So far, the transgenic adenocarcinoma mouse prostate cancer cells is androgen sensitive, their proliferation is not af-(TRAMP) is the only mouse prostate cancer model that profected by androgen withdrawal. The property of androgen-indegresses beyond the PIN lesion. However, this SV40 T antigen pendent growth observed in Pten null prostate cancers may transgenic model has high neuroendocrine differentiation pocontribute to hormone-resistant prostate cancer formation. Fitential (Garabedian et al., 1998) , a phenotype morphologically nally, Pten homozygous deletion leads to gene expression and biologically distinct from the adenocarcinomas seen in most changes seen in human prostate cancers and shares similarities human prostate cancers (Powell et al., 2003) . The SV40 T antiwith other human cancers with metastatic potentials. Thus, Pten gen model also has the limitation that the oncogene is driven prostate conditional knockout mice described in this study may by an androgen-dependent promoter and, therefore, it is not serve as a very useful tool for studying the molecular mechaan ideal model for studying the mechanism of androgen indenisms underlying prostate cancer metastasis and HRPC forpendence after androgen ablation. The attempt of genetic inactivation of several classic tumor suppressor genes, such as Rb1, mation. 
Prostate cancer metastasis
tumor population. This notion is primarily supported by animal models in which poorly metastatic cell lines can spawn highly Prostate cancers are known to metastasize; however, so far very little is known regarding the mechanisms governing prostate metastatic variants after multiple rounds of selection (Clark et al., 2000; Fidler and Kripke, 1977) . Recently, molecular signatures of cancer metastasis (Cher, 2001; Mundy, 2002) . The process of metastasis is often regarded as a multistep event, and each metastatic potential are found within the bulk of primary tumors (Ramaswamy et al., 2003; van 't Veer et al., 2002) , suggesting event must be successful for the entire process to occur. The successful metastatic cell must leave the primary site, enter that metastasis may be an intrinsic property inherited in the primary cancers. and survive in the lymphatic and blood circulatory systems, overcome host defenses, extravasate and grow as a metastatic Interestingly, the expressions of 3 out of 17 such signature genes were altered in the same directions in our model, indicatcolony (Fidler and Kripke, 2003) . Thus it is believed that the metastatic cell is a rare cell mixed within the heterogenous ing that the Pten conditional knockout mice may provide a Figure S1 ). Interestwere found in the lymph nodes and lung. Even though autopsy ingly, some of the genes known to be regulated by survey indicates possible metastatic foci in other organs, most NKX3.1 (Magee et al., 2003) , such as probasin, are also downof the metastasis lesions are very small and can be easily missed regulated in Pten null prostate cancers ( Figure 6A ). This result during histology sectioning. Thus, the actual rate of metastasis suggests that the mechanisms of Nkx3.1 loss of function in could be higher than what we have identified pathologically.
human prostate cancers may depend on the initial tumorgenic A unique property of prostate cancer is the frequently obevents. Indeed, synergistic effect of PTEN and NKX3.1 on tumor served bone metastasis and subsequent osteoblastic/osteoinitiation has been reported (Kim et al., 2002) . clastic lesions (Bubendorf et al., 2000; Cher, 2001; Harada et PSCA is another molecule that we identified by microarray al ., 1992; Mundy, 2002) . Even though we have not positively and confirmed to be upregulated in Pten null prostate cancer. identified colonies of prostate cancer cells in bone metastases, PSCA is expressed in almost all cases of high-grade PIN and we did observe dramatic bone remodeling activity in 3/11 aged is overexpressed in 40% of local and as many as 100% of bone Pten loxp/loxp ;Cre ϩ mice (data not shown). Our analyses also demetastatic prostate cancers (Gu et al., 2000) . Our array analysis tected increased osteopontin expression levels (Supplemental demonstrated that the expression of PSCA is upregulated by 14- Table S1 , and Z. Song, personal communication), an event fold in Pten null adenocarcinoma, consistent with our previous known to associate with the presence of bone metastasis in report that the percentage and intensity of mPSCA-positive cells men with prostate cancer (Hotte et al., 2002; Thalmann et al., increases dramatically in Pten mutant prostates (Dubey et al., 1999) . Further studies using sensitive imaging methodologies 2001). However, further experiments are necessary to distinand more prostate-specific markers will help to address this guish whether PSCA serves as a marker for a unique subpopulaissue.
tion of prostate epithelial cells associated with PTEN-controlled cell transformation or acts as an important player in the process Changes in gene expression profiling of prostate cancer formation caused by Pten loss. From the top 100 most significantly regulated genes of our Another robust upregulated gene is clusterin. Clusterin, also cDNA array analysis, we identified several genes that were well known as testosterone-repressed prostate message-2 (TRPM-2), documented in the literature for participating prostate cancer dimeric acid glycoprotein, and sulfated glycoprotein-2 (SGP-2), initiation, progression, and metastasis. is a highly conserved glycoprotein cloned from regressing rat One of the most interesting genes is Nkx3.1. Nkx3.1 is loventral prostate tissue. Recent studies implicated a protective cated in human chromosome 8p21, a region frequently deleted function of clusterin against apoptosis in several tissues (July in human prostate cancer (He et al., 1997), and its inactivation et al., 2002) . Clusterin may also be involved in the development has been shown to correlate with prostate cancer initiation and of androgen independence and resistance to chemotherapy progression (Bowen et al., 2000) . Interestingly, the mechanism (July et al., 2002; Steinberg et al., 1997 prostate cancer growth after androgen ablation therapy, or HRPC, has not been resolved to date.
Histology and immunochemistry analysis
What is the cellular origin of HRPC? The normal prostatic
Tissues are fixed in 10% buffered Formalin for 6-10 hr, followed by gentle wash and transfer to 70% alcohol. These paraffin-embedded tissues were epithelium consists of at least three cell types, basal cells, secre- present before hormone ablation therapy (Isaacs, 1999) or (2) For AR (PG-21, Upstate Biotechnology) and Nkx3.1 (DE#2, a kind gift cells that gained androgen independency due to additional ge- and PI3-kinase/AKT pathways in vivo, the effects will not be prostate were prepared on poly-lysine-coated glass microscope slides using significant in preventing androgen-sensitive cells from apoptoa robotic spotting tool as previously described (Aaltomaa et al., 1999) . Each array consisted of 10290 unique mouse cDNAs, 4511 of which were derived sis. Consistent with this notion, a recent study suggested that from cDNA libraries of developing and mature mouse prostate (http:// FKHR/AR complex may play an important role in protection of www.mpedb.org) . The remaining 5779 cDNAs were prostate cancer cells from apoptosis through AKT-independent chosen from the Research Genetics sequence-verified set of IMAGE clones pathway (Li et al., 2003) . Whether AKT activation will lead to (http://www.resgen.com/products/SVMcDNA.php3) and from the National androgen-independent cell proliferation, either mediated by AR Institute of Aging 15K set. The clone inserts were amplified by PCR, purified, and analyzed by gel electrophoresis. All PCR products were sequenceor independent of AR, remains to be investigated. Abdulkadir, S.A., Magee, J.A., Peters, T.J., Kallem, Z., Naughton, C.K., Humverified prior to spotting. Additional control cDNAs were included, and some phrey, P. A., and Milbrand, J. (2002) . Conditional loss of Nkx3.1 in adult mice clones were spotted twice for a total of 11552 features on the array.
induces prostatic intraepithelial neoplasia. Mol. Cell. Biol. 22, 1495-1503.
Probe construction, microarray hybridization, Backman, S., Stambolic, V., and Mak, T. (2002) . PTEN function in mammalian and data acquisition cell size regulation. Curr. Opin. Neurobiol. 12, 516-522. The protocol used for indirect labeling of cDNAs was described previously Bhatia-Gaur, R., Donjacour, A.A., Sciavolino, P.J., Kim, M., Desai, N., Young, (Pritchard et al., 2001) . Briefly, cDNA probes that incorporate aminoallyl P., Norton, C.R., Gridley, T., Cardiff, R.D., Cunha, G.R., Abate-Shen, C., and dUTP (aa-dUTP; Sigma-Aldrich) were made using 30 g of total RNA. Purified Shen, M.M. (1999) . Roles for Nkx3.1 in prostate development and cancer. cDNA from Pten null and age-matched wild-type prostates was labeled with Genes Dev 13, 966-977. either Cy3 or Cy5 monoreactive fluors (Amersham Life Sciences), combined, and competitively hybridized to microarrays under a coverslip for 16 hr at Bose, S., Crane, A., Hibshoosh, H., Mansukhani, M., Sandweis, L., and 63ЊC. Fluorescent array images were collected for Cy3 and Cy5 emissions Parsons, R. (2002) . Reduced expression of PTEN correlates with breast using a GenePix 4000B fluorescent scanner (Axon Instruments, Foster City, cancer progression. Hum. Pathol. 33, 405-409. California). Image intensity data were extracted and analyzed using GenePix Bowen, C., Bubendorf, L., Voeller, H.J., Slack, R., Willi, N., Sauter, G., Gasser, 4.0 microarray analysis software. RNA from four Pten null prostates and four T.C., Koivisto, P., Lack, E.E., Kononen, J., et al. (2000) . Loss of NKX3.1 age-matched wild-type prostates was analyzed using the microarray. Each expression in human prostate cancers correlates with tumor progression. experiment was performed in duplicate with reversal of the fluorescent label Cancer Res. 60, 6111-6115. to account for dye effects.
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